{"id":894048,"date":"2026-03-24T04:26:22","date_gmt":"2026-03-24T09:26:22","guid":{"rendered":"https:\/\/newsycanuse.com\/index.php\/2026\/03\/24\/is-asia-the-next-glp-1-boom-market-and-what-it-means-for-fb\/"},"modified":"2026-03-24T04:26:22","modified_gmt":"2026-03-24T09:26:22","slug":"is-asia-the-next-glp-1-boom-market-and-what-it-means-for-fb","status":"publish","type":"post","link":"https:\/\/newsycanuse.com\/index.php\/2026\/03\/24\/is-asia-the-next-glp-1-boom-market-and-what-it-means-for-fb\/","title":{"rendered":"Is Asia the next GLP\u20111 boom market and what it means for F&#038;B?"},"content":{"rendered":"<article id=\"pn_rw\" data-clarity-region=\"article\">\n<h2>Key Points Summary<\/h2>\n<ul>\n<li>Asia\u2019s GLP\u20111 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows<\/li>\n<li>China and India are driving demand shifts as diets westernise and metabolic disease climbs<\/li>\n<li>Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts<\/li>\n<li>Mintel forecasts \u201cexplosive growth\u201d, with China potentially becoming the world\u2019s No1 GLP\u20111 market by 2030<\/li>\n<li>Safety fears persist in China (side effects, \u201crebound\u201d, \u201csemaglutide face\u201d) and in India (strict rules on drug promotion)<\/li>\n<\/ul>\n<p>GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing \u2013 in most cases \u2013 a highly effective way to manage the ballooning issue of obesity in these markets. <\/p>\n<p>In Asia, the appetite for GLP-1 agonists for weight management has been less voracious. Cost and accessibility have been cited as the <a href=\"https:\/\/www.foodnavigator-asia.com\/Article\/2026\/02\/11\/glp-1-foods-in-asia\/\" target=\"_blank\" rel title=\"https:\/\/www.foodnavigator-asia.com\/Article\/2026\/02\/11\/glp-1-foods-in-asia\/\">main barriers to their use<\/a>, although there have been other issues moderating their uptake. <\/p>\n<p>\u201cIn many APAC markets where healthcare spending is largely out of pocket, adoption tends to be slower,\u201d explains FMCG consultant Veena Giridhar-Gopal, adding that the \u2018demand profile\u2019 has traditionally differed from that of western markets. <\/p>\n<p>\u201cAcross much of the region, GLP-1 therapies are more likely to be driven by diabetes and metabolic disease management than for weight loss.\u201d <\/p>\n<p><span>Also read \u2192 <\/span><a href=\"https:\/\/www.foodnavigator-asia.com\/Article\/2026\/02\/11\/glp-1-foods-in-asia\/\" target=\"_blank\" aria-label=\"Open related story\" rel=\"noreferrer\">GLP-1 foods in Asia: State of the market and key challenges<\/a><\/p>\n<p>That \u2018demand profile\u2019 has already started to shift. Obesity rates in most regions are on the rise \u2013 particularly in China and India, where many are edging away from traditional Asian diets to more calorific western-style food. As a result, governments are seeking swift solutions to manage their nations\u2019 increasing waistlines. <\/p>\n<p>Could GLP-1 agonists be the answer they are looking for?<\/p>\n<p>\u2018Yes\u2019, says Jonny Forsyth, principal strategist at Mintel Food &#038; Drink, who thinks we\u2019re set to see \u2018explosive growth\u2019 of GLP-1s in Asia this coming year. <\/p>\n<p>\u201cOur data shows that there is strong interest in GLP-1s for weight loss in Asia,\u201d he says. <\/p>\n<p>\u201cFor example, 68% of Indian adults would like to know how medications that reduce appetite can help with their own weight management, second only to Nigeria among the 36 different countries we polled.\u201d<\/p>\n<p>China is arguably most desperate for a quick solution to tackle rapidly growing rates of obesity. A recent survey in medical journal The Lancet suggests about half of adults and 20% of children are obese. <\/p>\n<p>Then there is the fact that Indian and Chinese companies are in late-stage trials with cheaper generics as the patent for semaglutide expires in Asia, adds Forsyth. <\/p>\n<p>\u201cThis has already forced Novo Nordisk to dramatically reduce prices of Ozempic, and if generics cost as little as US$100 per month or less, as mooted, that would make them accessible to a much wider user-base.\u201d <\/p>\n<p>If those cost and accessibility barriers were to lift, there are strong indications that GLP-1 usage could not only increase in Asia, but in some markets, overtake that in the west, says Mintel. <\/p>\n<p>\u201cAccording to our model, China has the potential to be the number one GLP-1 usage market in the world by 2030,\u201d confirms Forsyth. <\/p>\n<p>However, there are some hurdles GLP-1 manufacturers will need to leap before this happens in Asia\u2019s second most populated country. <\/p>\n<figure>\n<div><picture><source  media=\"(max-width: 768px)\"><source  media=\"(min-width: 769px) and (max-width: 1058px)\"><source  media=\"(min-width: 1059px)\"><img decoding=\"async\" data-chromatic=\"ignore\" alt=\"Ozempic injection pen with food\" src=\"https:\/\/www.foodnavigator-asia.com\/resizer\/v2\/DCJV7PNQDNCXVEIUKF7BE4OPYU.jpg?auth=a7f78e63c33ac5ca04f56b342e742080110fc553c2d7e34ba1ab6a2f4646ae0f&#038;smart=true\" loading=\"lazy\"><\/picture><\/div><figcaption><span>How will Asia&#8217;s increased take-up of GLP-1 impact F&#038;B?  (Svitlana Pietukhova\/Image: Getty \/ Svitlana Pietukhova)<\/span><\/figcaption><\/figure>\n<p>The side effects \u2013 some potentially fatal \u2013 reported by the Medicines and Healthcare Products Regulatory Agency (MHRA) and news reports across the west, highlighting how patients regain weight when they are no longer taking GLP-1s, could mean many Chinese patients will be anxious about taking these drugs. <\/p>\n<p>\u201cChinese consumers prioritise safety when they choose weight loss products, meaning the potential side effects of taking GLP-1 drugs, such as nausea, rebound effect and \u2018semaglutide face\u2019 may prevent people from taking this medicine for weight loss purposes,\u201d says Forsyth. <\/p>\n<p>In India, the government has also cautioned pharmaceutical companies against promoting prescription weight loss drugs, like GLP-1s, directly or indirectly to the public for fear patients will request them without proper medical evaluation. <\/p>\n<p>The statement from India\u2019s Central Drugs Standard Control Organisation (CDSCO) also said any campaign that promoted unrealistic expectations about weight loss would contravene Drugs Rules 1945. <\/p>\n<h2>Nutrient-rich foods<\/h2>\n<p>These concerns are all valid, but instances of the \u2018rebound effect\u2019 highlighted in the western press have been due to patients returning to their former eating habits when they stop taking the drug. <\/p>\n<p>GLP-1 agonist receptors work by mimicking a hormone made by the small intestine which regulates blood sugar levels, slows digestion and increases satiety after eating. In short, they curb the users\u2019 appetites so they eat less. <\/p>\n<p>Avoiding the rebound, therefore, lies in the GLP-1 patient\u2019s ability to embrace healthier eating while on the drugs and then sustaining these new habits when they finish taking them, explains UK dietician and nutritionist, Dr Sarah Schenker. <\/p>\n<p>So what exactly does \u2018healthier eating\u2019 mean in context of GLP-1 use and how can it be adopted during and after taking it to avoid weight returning? <\/p>\n<p>Schenker advocates \u2018squeezing nutrient-rich ingredients into smaller meals\u2019, for instance, adding fruit, nuts and seeds to salads, or to a protein like egg, fish or lean meats, while eschewing nutrient poor refined carbohydrates such as bread and white rice. <\/p>\n<p>\u201cIt\u2019s not all about calories, it\u2019s about getting nutrients from food,\u201d she explains, \u201cso you have to think more carefully about getting those nutrients from a smaller intake.\u201d <\/p>\n<p>Schenker says often high calorie carbohydrates \u2013 like rice and bread \u2013 serve as a vehicle to aid consumption of other foods, making them a no-go for those on a weight-loss journey. Instead, she suggests GLP-1 users swap these for less calorific options, such as other vegetables instead of rice, or noodles; or a lettuce leaf instead of bread. <\/p>\n<p>Incorporating protein into every meal is also advisable \u2013 both during and post-GLP-1 \u2013 to maintain muscle mass, something Schenker says Asian consumers typically do \u2013 consciously or not &#8211; already. This sets them off on the right foot for dietary habit changes. <\/p>\n<div>\n<blockquote cite=\"Jonny Forsyth, Mintel Food &#038; Drink\" data-style-direction=\"vertical\" data-style-justification=\"start\" data-style-alignment=\"unset\" data-style-inline=\"false\" data-style-wrap=\"nowrap\">\n<p>As GLP-1 adoption grows, demand for calorie-dense snacks, fast food, and ultra-processed foods is expected to decline<\/p>\n<p><span>Jonny Forsyth, Mintel Food &#038; Drink<\/span><\/p><\/blockquote>\n<\/div>\n<p>\u201cOne of the real positives about typical Asian diets that would work in favour of GLP-1 is that protein distribution throughout the day is better,\u201d she continues, pointing out that traditional Asian breakfasts often contain protein-rich beans and legumes, as opposed to refined carbohydrate-heavy typical western breakfasts of cereals and toast. <\/p>\n<p>These principles provide a stronger foundation for improved diets and suggest that Asia could experience sustained success if adopting GLP-1 agonist receptors for weight loss. This, teamed with Asia\u2019s \u2018openness to new technologies and a desire for a solution for weight management that actually works\u2019, add credence to the argument that GLP-1s will be well-received across this market, says Forsyth. <\/p>\n<p>Amy Stobie, a marketing and communications expert whose experience spans FMCG, healthcare, pharmaceuticals, and vitamins, minerals and supplements (VMS), says China\u2019s Healthy China Initiative, launched in 2019 makes it well-prepared to support citizens who are prescribed GLP-1s for weight loss. <\/p>\n<p>\u201cChina\u2019s health messaging has long framed obesity as a chronic disease, which has educated the population on the need to take a sustained approach to weight management,\u201d she says. <\/p>\n<p>In China, she notes, the healthcare system \u2018focuses on lifestyle and behavioural changes\u2019 which include the delivery of nutrition plans, counselling and exercise programmes from dedicated weight management centres. <\/p>\n<p>As dietician Schenker points out, GLP-1 patients who manage to keep the weight off when finish taking the drugs have done so because they\u2019ve changed eating habits and mindset for good. In China, GLP-1 agonists could therefore serve as the catalyst for weight loss before those crucial lifestyle changes kick in. <\/p>\n<p>China\u2019s package of healthcare support is impressive, but let\u2019s not forget that the reason it exists in the first place is to tackle high obesity rates.<\/p>\n<h2>How can FMCG support GLP-1 users?<\/h2>\n<p>And one of the reasons for growing obesity is bad diet with the increasing consumption of high-calorie fast food and snacks contributing. If GLP-1 is to work effectively, food brands with an existing presence in Asia will need to stop peddling high calorie snacks and step up as GLP-1 companions. <\/p>\n<p>So how can FMCG brands support &#8211; and benefit from \u2013 wider GLP-1 take up? <\/p>\n<p>Giridhar-Gohal, who has spent the last 25 years working in FMCG and retail with global corporations such as Diageo and PepsiCo, says there are opportunities for companies that can develop products that deliver high nutritional value in smaller formats, such as \u2018protein-forward snacks, fibre-rich foods that support satiety, portion-controlled products, and nutrient-dense mini-meals or functional beverages\u2019. <\/p>\n<p>\u201cIn Asian markets where food is deeply social and cultural, positioning around nourishment and quality is likely to resonate more strongly than traditional \u2018diet\u2019 framing,\u201d she adds. <\/p>\n<p>Forsyth says GLP-1 users will be actively seeking foods that deliver more nutrition in smaller portions, particularly high-protein, high-fibre snacks that are rich in vitamins in minerals. <\/p>\n<p><span>Also read \u2192 <\/span><a href=\"https:\/\/www.beveragedaily.com\/Article\/2026\/03\/04\/glp1-functional-drinks-market-set-for-rapid-global-growth\/\" target=\"_blank\" aria-label=\"Open related story\" rel=\"nofollow sponsored noreferrer\">GLP-1 drinks are taking off around the world<\/a><\/p>\n<p>He points towards brands like Nestl\u00e9 which launched GLP-1 companion brand Vital Pursuit \u2013 a range of portion-controlled high-protein, high fibre and nutrient dense ready meals &#8211; <a href=\"https:\/\/www.foodnavigator-asia.com\/Article\/2026\/01\/20\/3-must-watch-emerging-food-drink-categories-for-growth-in-2026\/\" target=\"_blank\" rel title=\"https:\/\/www.foodnavigator-asia.com\/Article\/2026\/01\/20\/3-must-watch-emerging-food-drink-categories-for-growth-in-2026\/\">in the US at the end of 2024<\/a> and <a href=\"https:\/\/www.dairyreporter.com\/Article\/2025\/08\/19\/how-danone-formulated-the-worlds-first-glp-1-friendly-yogurt\/\" target=\"_blank\" rel title=\"https:\/\/www.dairyreporter.com\/Article\/2025\/08\/19\/how-danone-formulated-the-worlds-first-glp-1-friendly-yogurt\/\">Danone with its GLP-1 friendly yoghurt Oikos Fusion<\/a>. <\/p>\n<p>There is some evidence that brands are already in this space in Asia. Healthcare company Abbott launched vanilla nutrition shake Protality \u2013 a product which specifically targets GLP-1 drug users to address nutrient deficiencies and muscle mass loss &#8211; in Korea. <\/p>\n<p>And last month, Nestl\u00e9 announced it was launching a new <a href=\"https:\/\/www.nestle.com\/media\/news\/vital-nutritional-drink-healthy-aging\" target=\"_blank\" rel title=\"https:\/\/www.nestle.com\/media\/news\/vital-nutritional-drink-healthy-aging\">\u2018science-backed nutritional drinks\u2019 range<\/a> &#8211; Nestl\u00e9 Vital \u2013 in Latin America with plans to launch it in Europe and Asia later this year. <\/p>\n<p>There are also a growing number of functional foods hitting the market, offering nutritional features that GLP-1 users seek. Innova Market Insights reports a 32% rise year-on-year in the number of <a href=\"https:\/\/www.foodnavigator-asia.com\/Article\/2026\/02\/16\/top-functional-ingredients-shaping-food-drink-in-2026\/\" target=\"_blank\" rel title=\"https:\/\/www.foodnavigator-asia.com\/Article\/2026\/02\/16\/top-functional-ingredients-shaping-food-drink-in-2026\/\">products carrying a high protein claim<\/a>. <\/p>\n<p>Stobie recommends brands, particularly in the VMS space, also investigate the products GLP-1 users will need to support their health to get ahead with NPD. <\/p>\n<figure>\n<div><picture><source  media=\"(max-width: 768px)\"><source  media=\"(min-width: 769px) and (max-width: 1058px)\"><source  media=\"(min-width: 1059px)\"><img decoding=\"async\" data-chromatic=\"ignore\" alt=\"A 3d rendering of pre-filled GLP-1 receptor agonist pens, used for the treatment of type 2 diabetes or for weight management. It's disposable or multi-dose reusable pen.\" src=\"https:\/\/www.foodnavigator-asia.com\/resizer\/v2\/57S6H5UBJRAKHJWT2PAMXZ3QRU.jpg?auth=d3c2d6c4cdc4645063eed50116a97f360567e2eaa7986a06997b015ffc375e17&#038;smart=true\" loading=\"lazy\"><\/picture><\/div><figcaption><span>Which side effects have been linked to GLP-1s? (Love Employee\/Getty Images)<\/span><\/figcaption><\/figure>\n<p>\u201cFor example, Ozempic slows digestion and reduces appetite,\u201d she explains. \u201cAs a result, many people become deficient in vitamin D, B12, iron and zinc. Skin can become saggy, which collagen supplements can help.\u201d <\/p>\n<p>There\u2019s also a chance for nutrition-led brands with a presence in China to integrate with the nation\u2019s wrap-around weight loss services, she says. <\/p>\n<p>\u201cThere are strong opportunities for FMCG brands that can work in synergy with this system. Brands that appear in a health setting develop credibility with patients, because the products are psychologically received to have the same quality and authority they receive from care providers.\u201d <\/p>\n<p>She advises a \u2018careful and deliberate\u2019 integration that would align brands with patients at every step \u2013 from initial visits to weight loss centres, right through to follow-up appointments post GLP-use. Tie-ups with non-food brands \u2013 in sportswear for example \u2013 could be the next step. <\/p>\n<p>\u201cConsumers using GLP-1 will want to see how a product fits into their lives and understand how it can support them.\u201d <\/p>\n<p>Returning to Giridhar-Gopal\u2019s earlier point about nourishment and quality, Forsyth thinks food or food with ingredients that bring more satiety, like konjak, and that attract consumers with \u2018natural GLP-1\u2019 as their selling point, will become more popular. <\/p>\n<p>Schenker agrees, suggesting that protein taken in a more natural food form \u2013 in yoghurt, fish or egg for example &#8211; rather than in processed powders or bars, will have greater appeal among those on GLP-1. <\/p>\n<p>Concluding, Forsyth predicts a see-saw affect with increasing GLP-1 agonist receptor use prompting a reorientation of category sales as manufacturers realise that consumers are changing what they put in their shopping baskets. <\/p>\n<p>\u201cAs GLP-1 adoption grows, demand for calorie-dense snacks, fast food, and ultra-processed foods is expected to decline, while healthier options, especially fruits, vegetables, and protein-rich foods, will see growth,\u201d he says. <\/p>\n<p> Diego Block <br \/><a href=\"https:\/\/www.foodnavigator-asia.com\/Article\/2026\/03\/16\/asias-glp1-boom-what-food-and-drink-brands-must-do\/?utm_source=RSS_Feed&#038;utm_medium=RSS&#038;utm_campaign=RSS\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Points Summary Asia\u2019s GLP\u20111 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price<\/p>\n","protected":false},"author":1,"featured_media":894049,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[148326,497],"tags":[148325,6634],"class_list":{"0":"post-894048","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-glp","8":"category-market","9":"tag-glp","10":"tag-market"},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts\/894048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/comments?post=894048"}],"version-history":[{"count":0,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts\/894048\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/media\/894049"}],"wp:attachment":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/media?parent=894048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/categories?post=894048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/tags?post=894048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}